Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock

by · The Cerbat Gem

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Robert Gut sold 25,613 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Robert Gut also recently made the following trade(s):

  • On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84.

uniQure Stock Up 4.0%

NASDAQ:QURE traded up $0.85 during trading hours on Wednesday, reaching $22.35. 1,443,119 shares of the company traded hands, compared to its average volume of 2,039,311. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The business’s 50-day moving average price is $25.06 and its two-hundred day moving average price is $27.73. The stock has a market capitalization of $1.39 billion, a P/E ratio of -5.09 and a beta of 0.68. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $4.46 million. Analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of research reports. Royal Bank Of Canada cut their price objective on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. UBS Group set a $95.00 price objective on uniQure in a research report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Leerink Partners decreased their price objective on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Finally, Wells Fargo & Company cut their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.82.

Get Our Latest Research Report on uniQure

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Private Trust Co. NA purchased a new stake in shares of uniQure in the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp boosted its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in uniQure in the third quarter valued at about $50,000. FNY Investment Advisers LLC raised its holdings in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.

Featured Stories